Click Here To Get Our Excluive stock At Your Door-Step

💊💊Save 15% On Your First Order

Order Oxycodone 15mg tablets — Clinical Reference Profile

Summary
Oxycodone is a semi-synthetic opioid analgesic prescribed for the treatment of moderate-to-severe pain. The 15mg strength is generally used in patients who have developed some opioid tolerance or who require more than the standard starting doses (5mg or 10mg) provide. As a DEA Schedule II substance, its prescribing and dispensing are tightly regulated due to abuse and dependence potential.

Mechanism and Pharmacokinetics
The drug acts as an agonist at mu-opioid receptors within the central nervous system, with secondary activity at kappa-opioid receptors, reducing the perception of pain. Following oral administration, bioavailability ranges from roughly 60% to 87%. The immediate-release formulation begins working within 10 to 30 minutes, reaches peak plasma concentration around the one-hour mark, and provides analgesic coverage for approximately 4 to 6 hours. Elimination half-life is roughly 3.2 hours. The drug undergoes hepatic metabolism, primarily through the CYP3A4 and CYP2D6 pathways, with metabolites cleared renally.

Clinical Indications
Prescribed when pain intensity warrants opioid-level intervention and non-opioid alternatives have proven insufficient. Common clinical contexts include post-operative recovery, oncologic pain management, and certain chronic pain conditions requiring ongoing physician oversight.

Dosing Framework
Prescribing follows an individualized approach accounting for pain severity, prior opioid exposure, and patient-specific risk indicators. Standard practice favors initiating at the lowest dose likely to be effective and limiting treatment duration to what is clinically necessary. Opioid-naïve patients generally require gradual titration rather than immediate use at this strength. Patients with impaired liver or kidney function typically need adjusted dosing. Final dosing decisions rest with the prescribing clinician.

Contraindications
Use is contraindicated in patients with significant respiratory depression outside of a monitored care setting, those with acute or severe asthma without monitoring capability, individuals with known or suspected bowel obstruction, and anyone with a hypersensitivity reaction to oxycodone or its formulation components.

Notable Drug Interactions
Co-administration with benzodiazepines or other central nervous system depressants raises the risk of excessive sedation and impaired breathing. Medications that inhibit CYP3A4 enzyme activity, including certain antifungals and antibiotics, can raise oxycodone blood levels. Conversely, CYP3A4-inducing medications may reduce the drug's effectiveness and trigger withdrawal symptoms. Use alongside MAO inhibitors is generally avoided due to serotonin syndrome risk. Alcohol consumption compounds central nervous system depression.

Populations Requiring Extra Caution
Use during pregnancy carries risk of withdrawal symptoms in the newborn. Older adults tend to be more sensitive to the drug's respiratory effects, warranting cautious dosing. Those with liver or kidney impairment need modified dosing regimens and closer clinical follow-up. First-time opioid users face elevated risk at this dosage strength and require careful, gradual introduction.

Prescribing Safeguards
Clinicians are encouraged to consult state Prescription Drug Monitoring Programs prior to and throughout treatment. Ongoing evaluation of pain relief, functional status, and any indicators of misuse is standard practice. For patients identified as higher-risk, co-prescribing naloxone is a recommended safeguard. Counseling on proper storage, disposal, and the dangers of sharing medication is part of standard patient education. Periodic drug screening may be incorporated based on clinical judgment.

Regulatory Classification
This medication falls under DEA Schedule II. Prescriptions must be written (verbal orders are restricted), refills are not automatically authorized, and the drug is governed by the FDA's Opioid Analgesic REMS program.

>>RELATED LINKS>>

https://my.pelotonia.org/profile/OR1373652

https://my.pelotonia.org/profile/OR1373771

https://my.pelotonia.org/profile/HH1370030